PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

TUMOR MARKERS IN PROSTATIC CANCER PATIENTS WITH POSITVE BONE SCAN, STAGE Tl-4 M1B (D2)
Article published in Urologia Polska 1996/49/4.

authors

Andrzej Stokłosa, Ewa Koźmińska, Andrzej W. Malewski, Andrzej Borkowski
Katedra i Klinika Urologii AM w Warszawie
Kierownik Kliniki: Prof. dr hab. med. A. Borkowski

keywords

prostate prostatic carcinoma bone metastases prostatic markers

summary

To evaluate the usefulness of measurement PSA, PAP (prostatic acid phosphatase),
and ALP (alkaline phosphatase) serum levels in detection of bone metastases in men
with newly diagnosed prostatic cancer (PC) we analysed 224 patients with PC in stage
Tl-4. In 162 patients (group I) PAP, ALP were determined, and bone scan (BS) was
performed (before PSA era). In 62 patients (group II) we measured PSA, PAP, ALP
serum levels and performed BS. The elevated ALP, PAP and PSA levels had 60%, 60%
and 90% (p < 0,02) of patients with positive bone scan respectively.
The patients with organ confined PC, with PSA < 20 ng/ml and elevated PAP, who
had moderately or poorly differentited tumors, were most likely to have bone metastases
and/or infiltration of prostatic capsule. It is concluded that the determination of tumor
markers is of value in Separation prostatic cancer patients with bone metastases at first
presentation. The bone scan does not provide additional information to PSA. In other
words, serum PSA levels below 10 ng/ml when combined with normal PAP and ALP
levels stand against the presence of advanced disease with very high realiability.

references

  1. [1] Bahnson, R., Catalona, W: Adverse implications of acid phosphatase levels in the
  2. upper range of normal. J. Urol. (1987), 137,427.
  3. [2] Chybowski, E, Larson Keller, J., Berstralh, E., Oesterling, J.: Predicting radionuclide
  4. bone scan findings in patients with newly diagnosed, untreated prostate cancer:
  5. Prostate specific antigen is superior to all others clinical parameters. J. Urol. (1991),
  6. 145, 313.
  7. [3] Ekman, R: Dilemma of microscopic lymph node metastases in human prostate
  8. cancer. Course program of Fourth European Urological Winter Forum, Davos,
  9. Szwajcaria (1995), 275-278.
  10. [4] Epstein, J., Piantadosi, S.: Management of stage D1 adenocarcinoma of the prosta-
  11. te. The Johns Hopkins experience 1974 to 1987. J. Urol. (1990), 144,1425.
  12. [5] Grabowski, M., Sikorski, A., Birkenfeld, B.\ Ocena korelacji scyntygrafii kośćca i
  13. PSA w raku stercza z przerzutami. Urol. Pol. (1994), 3A, 21.
  14. [6] Gutman, A., Gutman, E.: Acid phosphatase occurring in the serum of patients with
  15. metastazing carcinoma of prostate gland. J. Clin. Invest. (1938), 17,473.
  16. [7] Huggins, C, Hodges, C: Studies on prostatic cancer: The effect of castration, of
  17. estrogen and of androgen injection on serum phosphatases in metastatic carcinoma
  18. of the prostate. Cancer Res. (1941), 1,293.
  19. [8] Kulpa, I, Bugajski, A., Wójcik, E., Jaszczyński, J.: Objętość gruczołu a stężenie PAP
  20. i PSA u chorych na gruczolak stercza. Urol. Pol. (1994), 3,99.
  21. [9] Kuriyama, M., Wang, M., Lee, C, Killian, C, Papsidero, L., Inaji, H., Loor, R.,
  22. Lin, M., Nishiura, T., Slack, N., Murphy, G, Chu, T.: Use of human Prostate-specific
  23. antigen in monitoring prostate cancer. Cancer Res. (1981), 41,387.
  24. [10] Lowe, E, Trauzzi, S.: Prostatic acid phosphatase in 1993, its limited clinical utility.
  25. Urol. Clin. of North Amer. (1993), 20,4,589.
  26. [11] Lowe, E, Trauzzi, S.: Prostatic acid phosphataze in 1993. Its limited clinical utility.
  27. Urol. Clin. of North Amer. (1993), 20,4,589.
  28. [12] Malewski, A.: Rak stercza. Naturalna historia raka; niektóre aspekty wczesnego
  29. wykrycia. Medycyna 2000 (1993), 41/42, 42-44.
  30. [13] Myrtle, J., Klimley, P, hor, L., Brun, J.: Clinical utility of prostate specific antigen
  31. (PSA) in the management of prostate cancer. Advances in Cancer Diagnosis, Hy-
  32. britech. Inc. (1986).
  33. [14] Pawelski, S., Maj, S.: Normy i kliniczna interpretacja badań diagnostycznych w
  34. medycynie wewnętrznej. PZWL (1971), 4,123.
  35. [15] Porter, A.: Strontium-89 (Metastron) in the treatment of prostate cancer metastaic
  36. to bone. Eur. Urol. (1994), 21, SI, 20.
  37. [16] Romas, N., Kwan, D.: Prostatic acid phosphatase biomolecular features and assays
  38. for serum determination. Urol. Clin. of North Amer. (1993), 20,4,581.
  39. [17] Stamey, T., Kabalin, J.: Prostate specific antigen in the diagnosis and treatment of
  40. adenocarcinoma of the prostate. I. Untreated patients. J. Urol. (1989), 141,1070.
  41. [18] Stamey, T., Kabalin, /., McNeal, /.: Prostate specific antigen in the diagnosis and
  42. treatment of adenocarcinoma of the prostate. II: Radical prostatectomy treated
  43. patients. J. Urol. (1989), 141,1076.
  44. [19] Stokłosa, A.: Specyficzny antygen sterczowy w patologii gruczołu krokowego. Me-
  45. dycyna 2000 (1993), 41/42, 45.